US Bancorp DE raised its stake in shares of Coherus BioSciences, Inc. (NASDAQ:CHRS) by 90.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,406 shares of the biotechnology company’s stock after buying an additional 2,566 shares during the quarter. US Bancorp DE’s holdings in Coherus BioSciences were worth $75,000 at the end of the most recent quarter.
Other institutional investors have also bought and sold shares of the company. BlackRock Inc. lifted its position in shares of Coherus BioSciences by 6.5% in the first quarter. BlackRock Inc. now owns 11,210,180 shares of the biotechnology company’s stock worth $163,782,000 after buying an additional 681,830 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Coherus BioSciences by 4.9% during the 1st quarter. JPMorgan Chase & Co. now owns 5,196,106 shares of the biotechnology company’s stock valued at $75,915,000 after purchasing an additional 242,524 shares during the last quarter. Perceptive Advisors LLC lifted its holdings in shares of Coherus BioSciences by 0.6% during the 1st quarter. Perceptive Advisors LLC now owns 4,697,612 shares of the biotechnology company’s stock valued at $68,632,000 after purchasing an additional 25,776 shares during the last quarter. Alliancebernstein L.P. increased its position in shares of Coherus BioSciences by 7.4% in the 2nd quarter. Alliancebernstein L.P. now owns 4,504,274 shares of the biotechnology company’s stock valued at $62,294,000 after acquiring an additional 308,905 shares during the period. Finally, Aristotle Capital Boston LLC increased its position in shares of Coherus BioSciences by 17.9% in the 1st quarter. Aristotle Capital Boston LLC now owns 2,101,687 shares of the biotechnology company’s stock valued at $30,706,000 after acquiring an additional 318,607 shares during the period.
CHRS stock opened at $17.39 on Tuesday. The company has a debt-to-equity ratio of 1.84, a quick ratio of 2.16 and a current ratio of 2.30. The stock has a market cap of $1.33 billion, a P/E ratio of -7.50 and a beta of 1.02. The firm has a 50 day simple moving average of $14.43 and a 200 day simple moving average of $14.39. Coherus BioSciences, Inc. has a 52 week low of $12.21 and a 52 week high of $22.22.
A number of research firms have recently commented on CHRS. Maxim Group began coverage on Coherus BioSciences in a research report on Friday, August 6th. They set a “buy” rating and a $22.00 target price on the stock. Zacks Investment Research downgraded shares of Coherus BioSciences from a “hold” rating to a “sell” rating in a report on Monday, August 16th. Finally, HC Wainwright lifted their price objective on shares of Coherus BioSciences from $26.00 to $36.00 and gave the stock a “buy” rating in a research report on Friday, July 23rd. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, Coherus BioSciences presently has a consensus rating of “Buy” and a consensus price target of $26.33.
Coherus BioSciences Profile
Coherus BioSciences, Inc is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and Coherus COMPLETE. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.
Want to see what other hedge funds are holding CHRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Coherus BioSciences, Inc. (NASDAQ:CHRS).
Receive News & Ratings for Coherus BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.